Search the Newsreel

Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, …

MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook

Myriad Genetics Inc. (MYGN) stock slid by 45.72% after the company slashed its 2026 revenue outlook to $770M-$790M from a prior $860M-$880M, falling short of Street expectations. This reduction was attributed to competitive genetic testing advancements, weaker Q2 performance, and increased payer friction, leading …

Is MYR Group (MYRG) Using Record Backlog and M&A Firepower to Redefine Its Infrastructure Role?

MYR Group (MYRG) recently reported strong Q2 2026 results with increased sales, net income, and a record backlog, driven by demand in Transmission & Distribution and Commercial & Industrial sectors. The company also indicated plans for future acquisitions and share repurchases, leveraging its credit …

Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears

Myriad Genetics (MYGN) stock sharply declined by nearly 47% after reporting a Q2 revenue reset and cutting full-year sales guidance, deepening fears of prolonged losses. Despite some clinical advancements in its oncology portfolio, the company experienced weakened average revenue per test and reduced gross …

Could MYR Group (MYRG) Be 23% Undervalued Following Record Q2 Results And Acquisitions?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. MYR Group (MYRG) has drawn fresh attention after reporting record second quarter 2026 revenue, …

MYR Group (MYRG) Stock Sees Modest Fair Value Cut As Analysts Split On Upside

Analysts are split on the future of MYR Group (MYRG) stock, with a recent fair value estimate cut from US$455 to US$433. While some analysts are bullish due to increased EBITDA forecasts and strong backdrops for electrical T&D services, others are cautious, citing valuation …

5,000 Shares in MYR Group, Inc. $MYRG Bought by Axiom Investment Management LLC

Axiom Investment Management LLC recently acquired 5,000 shares of MYR Group, Inc. (NASDAQ:MYRG) for approximately $1.41 million, making it their 24th largest holding. Other institutional investors like Bank of America Corp DE, Amundi, and California State Teachers Retirement System also adjusted their stakes in …

Myriad Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2026-08-01

Myriad Genetics, Inc. (MYGN) released its Q2 2026 earnings call presentation, detailing financial results. The company reported an EPS of -$0.25, missing estimates by $0.19, and revenue of $190.70M, which was down 10.51% year-over-year and missed estimates by $15.33M. This article provides access to …

MYR Group (MYRG) Plans Acquisitions As Strong Finances Open New Growth Options

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. MYR Group (NasdaqGS:MYRG) has announced plans to actively pursue acquisitions. The company indicated on …

Myriad Genetics Is Maintained at Hold by TD Cowen

TD Cowen has reiterated its "Hold" rating for Myriad Genetics. The investment bank has also maintained its price target for the company.

Are Options Traders Betting on a Big Move in MYR Group Stock?

Investors in MYR Group Inc. MYRG need to pay close attention to the stock based on moves in the options market lately. That is because the October 16, 2026 $160.00 Call had some of the highest implied volatility of all equity options today. What …

Precision Trading with Myr Group Inc. (MYRG) Risk Zones

This article provides a detailed analysis of Myr Group Inc. (MYRG) stock, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors. The …

Vanguard Portfolio Management (MYRG) discloses 5.43% beneficial stake in MYR Group

Vanguard Portfolio Management LLC has disclosed a 5.43% beneficial ownership stake in MYR Group Inc (MYRG) common stock, totaling 846,723 shares. This information comes from a Schedule 13G filing, indicating Vanguard has sole voting power over 14,821 shares and sole dispositive power over all …

MYR Group Q2 Earnings Beat Estimates, Backlog Hits Record

MYR Group, Inc. MYRG reported strong second-quarter 2026 results, with both earnings and revenues surpassing expectations. The specialty electrical contractor benefited from solid demand across its end markets, particularly in commercial and industrial construction, while backlog climbed to a record level. Management highlighted continued …

[10-Q] MYRIAD GENETICS INC Quarterly Earnings Report

Myriad Genetics Inc. (MYGN) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The company reported a net loss of $43.2 million for Q2 2026 and $77.3 million for the six months ended June 30, 2026. Revenue experienced …

Renaissance Technologies LLC Cuts Stock Holdings in MYR Group, Inc. $MYRG

Renaissance Technologies LLC has reduced its stake in MYR Group, Inc. by 10.4% in the first quarter, selling 7,700 shares and retaining 66,300 shares valued at approximately $18.7 million. Several other hedge funds also adjusted their positions, and institutional investors now collectively own 88.9% …

MYR Group Inc (MYRG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of MYR Group Inc (MYRG), noting its current valuation score is 6.71 and ranks 34th in the Construction & Engineering industry. It highlights the company's P/E ratio of 36.26, which is significantly below its recent high but above …

Myriad Genetics (NASDAQ:MYGN) Posts Earnings Results, Misses Estimates By $0.22 EPS

Why Myriad Genetics (MYGN) Shares Are Falling Today

Why Myriad Genetics (MYGN) Shares Are Falling Today What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing second-quarter 2026 results that missed Wall Street's expectations and included a reduced full-year forecast. Revenue …

Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

Myriad Genetics Inc. (NASDAQ: MYGN) shares dropped significantly by 37.80% in after-hours trading after the company reported disappointing second-quarter 2026 financial results, including lower revenue, an operating loss, and reduced full-year revenue guidance. The company also suspended its adjusted EBITDA outlook. Despite the overall …

Myriad outlines $770M-$790M 2026 revenue and 66%-67% gross margin ranges while suspending adjusted EBITDA guidance

Earnings Call Insights: Myriad Genetics (MYGN) Q2 2026 MANAGEMENT VIEW * "Second quarter total revenue of $190.7 million was down 11% year-over-year, as volume decreased 1% and revenue per test decreased 9%." (President, CEO & Director Samraat Raha) "Demand for our Cancer Care Continuum …

Myriad Genetics Inc (MYGN) (Q2 2026) Earnings Call Highlights: Revenue Declines 11% Amid Payer ...

This article first appeared on GuruFocus. Total Revenue: $190.7 million, down 11% year over year. Test Volume: Decreased 1% year over year. Average Revenue per Test: Decreased 9% year over year, including an $11 million headwind from lower prior period collections. Cancer Care Continuum …

MYR Group Releases Q2 2026 Financial Results

MYR Group Inc. reported strong Q2 2026 financial results, with diluted earnings per share of $3.17, significantly surpassing Wall Street estimates. The company's revenue climbed to $1.08 billion, exceeding forecasts, driven largely by its Commercial & Industrial segment. MYR Group's backlog of $3.16 billion …

Myriad Genetics Lowers FY26 Rev Outlook

Myriad Genetics announced a reduction in its revenue outlook for fiscal year 2026. The company did not provide specific reasons for the revised forecast in the provided content.

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics announced its second quarter 2026 financial results, with revenue of $190.7 million, an 11% decrease year-over-year. The company is implementing new initiatives, including "Ascend," to improve efficiency, productivity, and scalability, and revised its full-year 2026 financial guidance. Despite challenges in Prenatal Health …

Myriad Genetics Q2 Results: Revenue falls 11% YoY

Myriad Genetics Inc. experienced an 11% year-over-year revenue decline to $190.7 million in Q2 2026, leading to a significant 37.8% drop in stock price. The company reported a $38.9 million operating loss and suspended its full-year adjusted EBITDA guidance due to payer friction and …

Myriad Genetics (NASDAQ: MYGN) posts Q2 loss, lowers 2026 revenue view

Myriad Genetics (NASDAQ: MYGN) reported a Q2 2026 net loss of $43.2 million on revenues of $190.7 million, marking an 11% year-over-year decline. The company also lowered its full-year 2026 revenue guidance to $770–$790 million and suspended its Adjusted EBITDA outlook, citing challenges in …

Earnings call transcript: Myriad Genetics sinks after Q2 2026 revenue miss

Myriad Genetics reported Q2 2026 revenue of $190.7 million, missing Wall Street forecasts, and posted an adjusted loss of $0.25 per share, wider than expected. Shares fell sharply by over 31% in after-hours trading. The company cut its full-year revenue guidance and suspended adjusted …

Myriad Genetics Q2 Loss Narrows; Revenue Falls 11%

(RTTNews) - Myriad Genetics, Inc. (MYGN) on Thursday reported a narrower loss for the second quarter despite a 11% decline in revenue, as last year's results were affected by a hefty goodwill impairment charge. The molecular diagnostics company also lowered its full-year 2026 revenue …

MYR Group Jumps 6.8% on EPS Beat

MYR Group Inc. saw its stock surge by 6.8% after reporting second-quarter 2026 earnings that significantly exceeded Wall Street expectations. The company achieved an EPS of $3.17, beating estimates by 20.1%, and revenue of $1.08 billion, demonstrating strong operational performance. This outperformance in a …

Press Release: MYR Group Inc. Announces Second-Quarter and First-Half 2026 Results

MYR Group Inc. (MYRG) announced its financial results for the second quarter and first half of 2026. This press release will provide details on the company's performance during these periods, likely including key financial metrics and highlights.

Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%

Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2026 sales of $190.7 million, falling short of analyst estimates, and a non-GAAP loss of $0.25 per share, significantly below consensus. The company also lowered its full-year revenue guidance to $780 million at the midpoint from an earlier $870 …

MYR Group, Inc. $MYRG Shares Acquired by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership significantly increased its stake in MYR Group, Inc. (NASDAQ:MYRG) by 220.5% in the first quarter, now holding 101,072 shares valued at $28.5 million. This comes as institutional investors collectively own 88.9% of the company. Despite MYR Group reporting strong quarterly …

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Earnings call transcript: Emyria posts 210% revenue growth in Q4 2026

MYR Group (NASDAQ:MYRG) Issues Earnings Results, Beats Expectations By $0.55 EPS

MYR Group (NASDAQ:MYRG) reported strong quarterly earnings, surpassing analyst estimates with an EPS of $3.17 against a consensus of $2.62, and revenues of $1.08 billion against $995.74 million. Despite beating expectations, the stock fell 5.5% to $322.06, trading below its 50-day moving average. Insider …